Chloe Kim Is Changing the Conversation Around ADHD in Women with Qelbree® for ‘Ms. Represented’ Campaign

Qelbree has reached approximately 3 million prescriptions filled since its launch in 2021.

Rhea-AI Summary

Supernus Pharmaceuticals (SUPN) has added professional snowboarder Chloe Kim as a paid spokesperson for its Qelbree ‘Ms. Represented’ campaign. Kim, who was diagnosed with attention-deficit/hyperactivity disorder (ADHD) as an adult, shares her experience to help the campaign connect with younger women.

Qelbree, a prescription non-stimulant ADHD treatment for adults and children ages 6 and older, has reached approximately 3 million prescriptions filled since its launch in 2021. The campaign launched last year.

Positive

• Minor pointApproximately 3 million Qelbree prescriptions have been filled since launch in 2021.

Negative

• None.

Key Figures

Prescriptions filled: Approximately 3 million prescriptions

Prescriptions filled

Approximately 3 million prescriptions

Qelbree since launch in 2021

Historical Context

1 past event · Latest: Aug 31

1 event

1. Aug 31

   Partnership

   24h Move

   +1.1%

   Announced Chloe Kim as compensated Qelbree ambassador to raise adult ADHD awareness.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

adhd, monoamine oxidase inhibitor, bipolar disorder, boxed warning

4 terms

adhd medical

"personal attention-deficit/hyperactivity disorder (ADHD) journey"

Attention-deficit/hyperactivity disorder (ADHD) is a common brain condition that makes it hard for people to focus, control impulses, and sit still—like having a car with strong accelerator and less-effective brakes for attention and activity. For investors, ADHD matters because it drives demand for medications, therapy, digital tools, and education supports, affects workplace productivity and healthcare costs, and is subject to regulatory approvals and insurance coverage decisions that influence market opportunities.

monoamine oxidase inhibitor medical

"a monoamine oxidase inhibitor (MAOI)"

A monoamine oxidase inhibitor (MAOI) is a type of drug that blocks an enzyme responsible for breaking down certain brain chemicals involved in mood, such as serotonin and dopamine. For investors, MAOIs matter because they can be effective treatments but carry strong safety risks and food or drug interaction restrictions, which affect regulatory approval, prescribing rates, labeling, and market size — think of them as powerful tools that require strict handling rules.

bipolar disorder medical

"patients with bipolar disorder"

A mental health condition marked by repeated swings between very low mood and energy (depressive episodes) and unusually high mood or activity (manic or hypomanic episodes), where these shifts are more extreme than normal ups and downs. Investors care because it affects healthcare demand, workplace productivity, insurance costs, and the market value of companies that develop treatments or provide care—think of it like sudden stormy weather that can change forecasts for costs and revenues.

boxed warning regulatory

"including Boxed Warning, and Medication Guide"

A boxed warning is the strongest safety alert a drug regulator places on a medication’s official label to highlight life‑threatening or very serious risks, similar to a bold red flag attached to a product. For investors, it matters because this warning can reduce sales, increase regulatory scrutiny, raise liability and monitoring costs, and change market perception of the drug’s future revenue and risk profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• The ‘Ms. Represented’ campaign expands its reach with professional snowboarder Chloe Kim, who shares her ADHD experience to help connect with a younger generation of women.
• More than 60% of U.S. women who reported ever receiving an ADHD diagnosis were first diagnosed in adulthood, underscoring the importance of recognizing experiences that don't fit familiar perceptions of the condition.¹
• Chloe is partnering with Qelbree, the #1 prescribed branded non-stimulant ADHD medication as of May 2026 which has reached approximately 3 million prescriptions filled since launch in 2021.*
  

ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Professional snowboarder Chloe Kim is bringing her personal attention-deficit/hyperactivity disorder (ADHD) journey to ‘Ms. Represented,’ a campaign from Supernus Pharmaceuticals for Qelbree (viloxazine extended-release capsules), a once-a-day, non-stimulant ADHD treatment for people ages 6 years and older. Diagnosed with ADHD as an adult, Chloe didn’t recognize her own experience in familiar portrayals of ADHD. Now, as a paid spokesperson for Supernus, she is opening up about her journey to change the conversation and help other women feel seen, understood, and represented.

Launched last year, the ‘Ms. Represented’ campaign challenges the narrow perceptions of ADHD that can leave women feeling misrepresented. Boys are nearly twice as likely as girls to be diagnosed with ADHD, while the percentage of women ages 23–49 newly diagnosed with the condition nearly doubled between 2020 and 2022.^2,3 While ADHD is often associated with hyperactivity and impulsivity, it can also involve inattentive symptoms, including less visible experiences such as getting easily distracted or having difficulty with organization.⁴ For Chloe, recognizing patterns in her own experiences helped her better understand her ADHD diagnosis, bringing another perspective to the campaign and helping connect with a younger generation of women.

“When I was diagnosed with ADHD, so much about what I had been experiencing finally made sense,” said Chloe. “I hope that by sharing my story, more women feel empowered to ask questions, seek support, and know that having ADHD doesn’t limit what they’re capable of achieving.”

Following Chloe’s diagnosis, she explored treatment options with her doctor and now takes once-a-day, non-stimulant Qelbree to help manage her ADHD symptoms. Initially approved for children ages 6-17 years in April 2021 and subsequently for adults in April 2022, Qelbree offers a treatment option for the nearly 16 million adults and 7 million adolescents living with ADHD in the U.S.^5,6

“Through the ‘Ms. Represented’ campaign, we're continuing to challenge the misconceptions that have left women's experiences with ADHD overlooked for too long,” said Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. “Chloe brings an important perspective to that mission, and as we mark five years of Qelbree, we remain committed to raising awareness and providing a non-stimulant treatment option to help people manage their ADHD symptoms.”

Designed to inspire action, the ‘Ms. Represented’ campaign meets women where they are, using engaging storytelling to spark vital health conversations. By connecting the dots across her passions, from snowboarding, fashion to mental health, Chloe brings the initiative to life in editorial collaborations with Coveteur and PureWow, alongside an appearance on a social-first episode of Are You Okay?.

To learn more about Chloe's story and the ‘Ms. Represented’ campaign, visit www.qelbree.com/msrepresented. For more information about Qelbree, visit www.qelbree.com.

*Qelbree’s pediatric indication was approved for children ages 6-17 years in April 2021.

INDICATION

Qelbree^® (viloxazine extended-release capsules) is a prescription medicine used to treat ADHD in adults and children 6 years and older.

IMPORTANT SAFETY INFORMATION

Qelbree may increase suicidal thoughts and actions, in children and adults with ADHD, especially within the first few months of treatment or when the dose is changed. Tell your doctor if you or your child have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your or your child’s moods, behaviors, thoughts, and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

You or your child should not take Qelbree if you or your child:
Take a medicine for depression called a monoamine oxidase inhibitor (MAOI) or have stopped taking an MAOI in the past 14 days. Also, you or your child should avoid alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline.

Qelbree can increase blood pressure and heart rate. Your or your child’s doctor will monitor these vital signs.

Qelbree may cause manic episodes in patients with bipolar disorder. Tell your doctor if you or your child show any signs of mania.

Do not drive or operate heavy machinery until you know how Qelbree will affect you or your child. Qelbree may cause you or your child to feel sleepy or tired.

The most common side effects of Qelbree in patients 6 to 17 years are sleepiness, not feeling hungry, feeling tired, nausea, vomiting, trouble sleeping, and irritability, and in adults, insomnia, headache, sleepiness, tiredness, nausea, decreased appetite, dry mouth, and constipation. These are not all the possible side effects of Qelbree.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information, including Boxed Warning, and Medication Guide here.

Qelbree (viloxazine extended-release capsules) is available in 100 mg, 150 mg and 200 mg capsules.

About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.

For more information, please visit www.supernus.com.

Qelbree is a registered trademark of Supernus Pharmaceuticals, Inc.
©2026 Supernus Pharmaceuticals, Inc. All rights reserved.

1. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics Rapid Surveys System, Round 2: ADHD. October–November 2023. https://www.cdc.gov/nchs/rss/round2/adhd.html   
2. Reuben C., Elgaddal N. (2024) Attention-deficit/hyperactivity disorder in children ages 5–17 years: United States, 2020–2022. NCHS Data Brief, no 499. Hyattsville, MD: National Center for Health Statistics.
3. Russell, J., et al. (2023). Number of ADHD Patients Rising, Especially Among Women. Epic Research.
4. Quinn, P.O. and Madhoo, M. (2014). A Review of Attention Deficit/Hyperactivity Disorder in Women and Girls: Uncovering This Hidden Diagnosis. Prim Care Companion CNS Disord.
5. Centers for Disease Control and Prevention (CDC). ADHD in Adults: An Overview. October 8, 2024. https://www.cdc.gov/adhd/articles/adhd-across-the-lifetime.html
6. CDC. Data and Statistics on ADHD. November 19, 2024. https://www.cdc.gov/adhd/data/index.html

CONTACTS:

Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591

Or

INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com

Or

MEDIA CONTACT:
Diana Torres-Bixby
Burson
(917) 686-0517
diana.torres-bixby@bursonglobal.com

QBE.2026-0317